Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

• ClinicalTrials.gov Identifier: NCT00774800
• Recruitment Status: Completed
• First Posted: October 17, 2008
• Results First Posted: September 5, 2014
• Last Update Posted: February 26, 2019
• Sponsor: Halozyme Therapeutics
• Information provided by (Responsible Party): Halozyme Therapeutics

Study Description

Brief Summary:

Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with both Humalog and Humulin-R in order to determine if it improves the absorption of these insulins to more closely mimic the body's natural increase in insulin in response to a meal.

Condition or disease	Intervention/treatment	Phase
Type 1 Diabetes Mellitus	Drug: Humalog; Drug: Humulin-R; Drug: Recombinant human hyaluronidase PH20 (rHuPH20); Other: Liquid meal	Phase 2

Detailed Description:

Participants received all 4 interventions in the same order.

Dose-finding visits were conducted to identify the appropriate dose of Humalog and Humulin-R. For each Humalog dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). For each Humulin-R dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humulin-R, corresponding to a mass concentration of 20.0 μg/mL rHuPH20 (at final concentration of 100 U/mL of Humulin-R).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 22 participants
• Intervention Model: Crossover Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humulin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients
• Study Start Date: October 2008
• Actual Primary Completion Date: March 2009
• Actual Study Completion Date: March 2009

Arms and Interventions

Arm

Intervention/treatment

Experimental: First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R; Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified. Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal. Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified. Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal. Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL. All dose finding visits and interventions were separated by 3-10 days.

Drug: Humalog; Other Name: Insulin lispro; Drug: Humulin-R; Other Names: Humulin; Recombinant human insulin; Drug: Recombinant human hyaluronidase PH20 (rHuPH20); Other Names: HYLENEX; PH20; Other: Liquid meal; Other Name: Ensure

Outcome Measures

Primary Outcome Measures :

1. Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60) [ Time Frame: Predose up to 60 minutes postdose ]
   AUC was derived as the area under the serum insulin concentration profile from 0 to time "t." Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; and at 20, 30, 45, and 60 mins postdose.

Secondary Outcome Measures :

1. Maximum Serum Insulin Concentration (Cmax) [ Time Frame: Predose up to 480 minutes postdose ]
   Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
2. Time to Maximum Serum Insulin Concentration (Tmax) [ Time Frame: Predose up to 480 minutes postdose ]
   Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
3. Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG]) [ Time Frame: Predose up to 4 hours after injection of study drug ]
   AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 140 milligrams per deciliter (mg/dL) within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before; at 3, 6, 9, 12, 15, 20, 25 minutes; and every 10 minutes from minute 30 to 240 postdose.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female of age 18 to 65 years, inclusive. Females of child-bearing potential must use a standard and effective means of birth control for the duration of the study.
• Participants with Type 1 diabetes mellitus treated with insulin for greater than or equal to 12 months.
• Body mass index (BMI) 18.0 to 29.0 kilograms per meter squared (kg/m^2), inclusive.
• Glycosylated hemoglobin A1c (HbA1c) less than or equal to 10% based on local laboratory results.
• Fasting C-peptide less than 0.6 nanograms per milliliter (ng/mL).
• Current treatment with insulin less than 1.2 units per kilogram per day (U/kg/day).
• Participants should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug injections and assessments required in this protocol.

Exclusion Criteria:

• Known or suspected allergy to any component of any of the study drugs in this trial.
• Previous enrollment in this trial.
• A participant who has proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.
• Clinically significant (as judged by the Investigator) active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on electrocardiogram [ECG]), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure greater than or equal to 100 millimeters of mercury [mmHg] and/or systolic blood pressure greater than or equal to 160 mmHg after 5 minutes in the supine position).
• History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the participant.
• Clinically significant findings (as judged by the Investigator) in routine laboratory data, including anemia with hemoglobin less than lower limits of normal at screening.
• Use of drugs which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia.
• Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator.
• Current addiction to alcohol or substances of abuse as determined by the Investigator.
• Blood donation (>500 milliliters [mL]) within the 9 weeks prior to first day of dosing on study.
• Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives or barrier methods).
• Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation.
• Symptomatic gastroparesis.
• History or evidence of use of any tobacco- or nicotine-containing product within 6 months of screening or screening quantitative urine nicotine concentration >50 ng/mL.
• Receipt of any investigational drug within 4 weeks of first day of dosing in this study.
• Any condition (intrinsic or extrinsic) that in the judgment of the Investigator will interfere with trial participation or evaluation of data.

Contacts and Locations

Locations

United States, California

Profil Institute for Clinical Research, Inc.

Chula Vista, California, United States, 91911

Sponsors and Collaborators

Halozyme Therapeutics

Investigators

• Principal Investigator: Linda A Morrow, M.D.; Profil Institute for Clinical Research, Inc.

More Information

Publications of Results:

Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care. 2011 Mar;34(3):666-8. doi: 10.2337/dc10-1892. Epub 2011 Jan 27.

• Responsible Party: Halozyme Therapeutics
• ClinicalTrials.gov Identifier: NCT00774800
• Other Study ID Numbers: HZ2-08-05; HALO-117-201 ( Other Identifier: Halozyme Therapeutics, Inc. )
• First Posted: October 17, 2008
• Results First Posted: September 5, 2014
• Last Update Posted: February 26, 2019
• Last Verified: February 2019

Keywords provided by Halozyme Therapeutics:

Recombinant Hyaluronidase; Type 1 Diabetes Mellitus; Humalog; Humulin R; rHuPH20; Hylenex

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Insulin; Insulin, Globin Zinc; Insulin Lispro; Hypoglycemic Agents; Physiological Effects of Drugs